President Trump concluded agreements with pharmaceutical companies on the so-called the most favorable national determination of drug prices, which is to last for three years.[1][2] These agreements oblige drug manufacturers to offer American patients prices that match the lowest prices in other developed countries.[1] In December 2025, Trump announced nine new deals with big pharmaceutical companies that will bring billions of dollars in savings.[1] For example, Merck cut the price of its diabetes drug Januvia from $330 to $100 for patients buying directly through the TrumpRx program, and Novartis cut the price of its multiple sclerosis drug Mayzent from $9,987 to $1,137.[1] The agreements give all state Medicaid programs access to these reduced prices and obligate companies to offer new innovative drugs at prices determined to be the nation's most favorable.[1] Drugmakers have also pledged to increase investment in US manufacturing and in return will receive a three-year exemption from tariffs they would otherwise face.[2]